tvb-2640
Small moleculeexperimental
Clinical trial activity
14 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
7
Phase 3
2
Phase 4
0
Earliest trial started Nov 1, 2013 (NCT02223247)
Timeline
Indications
Studied for
Mechanism of action
- Fatty acid synthaseINHIBITOR
FASN inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1nc(-c2cc(C(=O)N3CCC(c4ccc(C#N)cc4)CC3)c(C)cc2C2CCC2)n[nH]1- Mol. weight
- 439.56 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3661754 ↗
Also known as
- tvb-2640
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07216313 | Phase 1 | Sep 30, 2025 | Sagimet Biosciences Inc. |
| NCT06692283 | Phase 3 | Jan 31, 2025 | Sagimet Biosciences Inc. |
| NCT06594523 | Phase 3 | Dec 31, 2024 | Sagimet Biosciences Inc. |
| NCT05835180 | Phase 1 | May 1, 2023 | Sagimet Biosciences Inc. |
| NCT05743621 | Phase 1 | Apr 30, 2023 | Cornell University, Sagimet Biosciences Inc. |
| NCT05657834 | Phase 1 | Nov 21, 2022 | Sagimet Biosciences Inc. |
| NCT04906421 | Phase 2 | Aug 12, 2021 | Sagimet Biosciences Inc. |
| NCT04352361 | Phase 1 | Apr 2, 2020 | Ascletis Pharmaceuticals Co., Ltd. |
| NCT03808558 | Phase 2 | Jun 1, 2019 | The University of Texas, Dallas |
| NCT03938246 | Phase 2 | Mar 22, 2019 | Sagimet Biosciences, University of California, San Diego |
| NCT03179904 | Phase 2 | Jul 30, 2017 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT03032484 | Phase 2 | Jun 10, 2017 | University of Texas, San Antonio |
| NCT02980029 | Phase 1 | Jan 1, 2017 | University of Kentucky |
| NCT02223247 | Phase 1 | Nov 1, 2013 | Sagimet Biosciences, SCRI Development Innovations |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sagimet Biosciences Inc. | For profit | 7 | 6 | 3 | 2021 |
| Sagimet Biosciences | For profit | 2 | 2 | 2 | 2013 |
| Ascletis Pharmaceuticals Co., Ltd. | For profit | 1 | 1 | 1 | 2020 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2017 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2017 |
| SCRI Development Innovations | For profit | 1 | 0 | 1 | 2013 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of California, San Diego | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Kentucky | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Texas, San Antonio | Academic/Hospital | 1 | 1 | 1 | 2017 |
11 organizations
Page 1 / 1